This study aims to validate the accuracy and clinical value of METTL3 as a biomarker for predicting immune therapy response in patients with urinary tract tumors through observational studies.

Inclusion Criteria:

1. Patients diagnosed with urinary system tumors through pathological examination;
2. Meet specific clinical stages and surgical treatment standards;
3. Intraoperative tissue resection meets the sample testing standards;
4. The patient is willing to participate in the study and sign an informed consent form.

Exclusion Criteria:

1. Not meeting the specific clinical stage and not receiving surgical treatment;
2. Abnormal mental behavior;
3. Intellectual disability;
4. Age under 18 years old or over 75 years old;
5. Low understanding and communication skills.

Patients with urological tumors